Twist Bioscience (NASDAQ:TWST) Shares Gap Down – Time to Sell?

Twist Bioscience Co. (NASDAQ:TWST) shares gapped down prior to trading on Monday . The stock had previously closed at $52.37, but opened at $45.30. Twist Bioscience shares last traded at $49.24, with a volume of 362,146 shares traded.

Wall Street Analysts Forecast Growth

TWST has been the topic of a number of recent research reports. Scotiabank upped their price objective on Twist Bioscience from $54.00 to $62.00 and gave the company a “sector outperform” rating in a research report on Tuesday. Barclays lowered their price target on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research report on Tuesday, November 19th. Robert W. Baird boosted their price objective on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research report on Tuesday. JPMorgan Chase & Co. raised their target price on shares of Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a report on Tuesday. Finally, TD Cowen reiterated a “buy” rating and set a $58.00 price target on shares of Twist Bioscience in a report on Tuesday, November 26th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $53.80.

Twist Bioscience Stock Performance

The stock’s 50-day moving average price is $48.63 and its 200 day moving average price is $46.21.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.27% and a negative net margin of 66.69%. The business had revenue of $88.70 million during the quarter, compared to analyst estimates of $86.96 million. During the same period in the previous year, the company posted ($0.75) EPS. Twist Bioscience’s revenue was up 24.1% on a year-over-year basis. As a group, research analysts anticipate that Twist Bioscience Co. will post -2.27 EPS for the current year.

Insiders Place Their Bets

In other Twist Bioscience news, COO Patrick John Finn sold 10,340 shares of Twist Bioscience stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $48.00, for a total value of $496,320.00. Following the transaction, the chief operating officer now owns 221,061 shares in the company, valued at $10,610,928. The trade was a 4.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Adam Laponis sold 5,886 shares of the stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $43.26, for a total transaction of $254,628.36. Following the sale, the chief financial officer now directly owns 110,096 shares of the company’s stock, valued at approximately $4,762,752.96. The trade was a 5.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 48,707 shares of company stock worth $2,343,623 in the last three months. Corporate insiders own 3.01% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. Massachusetts Financial Services Co. MA boosted its stake in Twist Bioscience by 215.9% in the third quarter. Massachusetts Financial Services Co. MA now owns 29,314 shares of the company’s stock valued at $1,324,000 after acquiring an additional 20,035 shares in the last quarter. Barclays PLC raised its stake in Twist Bioscience by 214.8% in the third quarter. Barclays PLC now owns 153,039 shares of the company’s stock valued at $6,913,000 after buying an additional 104,420 shares during the last quarter. FMR LLC boosted its holdings in Twist Bioscience by 6.0% in the third quarter. FMR LLC now owns 218,561 shares of the company’s stock worth $9,875,000 after acquiring an additional 12,327 shares in the last quarter. Avanza Fonder AB purchased a new stake in shares of Twist Bioscience during the fourth quarter worth about $1,059,000. Finally, BNP Paribas Financial Markets increased its holdings in shares of Twist Bioscience by 128.1% during the third quarter. BNP Paribas Financial Markets now owns 38,032 shares of the company’s stock valued at $1,718,000 after acquiring an additional 21,357 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.